Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Genmab ( (GMAB) ) has provided an update.
On January 22, 2025, Genmab A/S announced that the net sales of DARZALEX® (daratumumab) for the year 2024 totaled USD 11,670 million, with USD 6,588 million generated in the U.S. and USD 5,082 million in the rest of the world. Genmab receives royalties on these sales from Johnson & Johnson, which holds the exclusive worldwide license to develop, manufacture, and commercialize daratumumab. This significant sales performance underscores Genmab’s strong positioning within the biotechnology industry and its successful collaboration with Johnson & Johnson, highlighting the continued market demand for DARZALEX® and its subcutaneous version, DARZALEX FASPRO®.
More about Genmab
Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, focused on developing innovative and differentiated antibody therapeutics. Established in 1999, Genmab has invented next-generation antibody technology platforms and maintains a robust pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and other immune-enhancing antibodies. The company operates internationally, with a presence in North America, Europe, and Asia Pacific, aiming to transform the lives of people with cancer and other serious diseases by 2030.
YTD Price Performance: 3.81%
Average Trading Volume: 1,249,147
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $13.61B
For detailed information about GMAB stock, go to TipRanks’ Stock Analysis page.
